Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Raises FY2023 Revenue Guidance on Higher NGS Sales

NEW YORK – Twist Bioscience said on Friday before the market opened that it is raising its full-year 2023 revenue guidance, ahead of the end of its fiscal year at the end of September.

The synthetic DNA maker now expects fiscal 2023 revenues in the range of $241 million to $242 million, up from previous guidance in the range of $235 million and $238 million, based on higher expected next-generation sequencing revenues, partially offset by lower biopharma revenues. The firm said that it expects NGS sales to total around $120 million for the year compared to previous guidance of $113 million to $114 million.

For the fiscal fourth quarter, the firm expects revenues of approximately $63 million to $64 million, R&D expenses of approximately $26 million, and SG&A expenses of about $47 million.

The news came with the firm's fiscal third quarter financial results. For the three months ended June 30, Twist reported $63.7 million in revenues, up 14 percent from $56.1 million in the prior-year period, beating Wall Street analysts' average estimate of $60.5 million.

The firm shipped approximately 171,000 genes in the quarter, up from 163,000 in Q3 2022.

Twist's research and development expenses for the quarter fell 33 percent to $24.5 million from $36.8 million in fiscal Q3 2022. Selling, general, and administrative expenses totaled $46.1 million, down 16 percent from $53.7 million a year ago. Twist also recorded $12.7 million in restructuring costs.

The firm's net loss for the quarter was $57.4 million, or $1.01 per share, compared to a net loss of $60.5 million, or $1.08 per share, in the year-ago quarter, beating the consensus Wall Street estimate of a loss of $1.14 per share.

The company ended the quarter with $307.5 million in cash and cash equivalents and $49.7 million in short-term investments.

In morning trading on the Nasdaq, shares of Twist were up 15 percent at $23.95.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.